Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HLS Therapeutics Inc. (HLS.TO)
Etobicoke, ON, CA
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.71% | -1.50% | -1.29% | +2.00% | -6.33% | -4.77% | -3.97% | +0.66% | -73.24% | -60.09% | -60.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-0.3% Q1'26: +0.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+35.5% ★ Q1'26: +48.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+28.1% ★ Q1'26: +49.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-7.4% Q1'26: -17.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-4.2% Q1'26: -9.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.0% ★ Q1'26: -1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.76× Q1'26: 3.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
75.08M
est: 72.14M (+4.1%)
|
61.42M
est: 60.23M (+2.0%)
|
54.16M
est: 52.59M (+3.0%)
|
56.11M
est: 55.26M (+1.5%)
|
60.01M
est: 60.14M (-0.2%)
|
61.47M
est: 63.51M (-3.2%)
|
63.07M
est: 43.07M (+46.4%)
|
56.62M
est: 56.76M (-0.2%)
|
56.47M
est: 55.11M (+2.5%)
|
57.27M
56.94M – 57.83M
+3.9% YoY
|
64.16M
61.99M – 66.32M
+12.0% YoY
|
76.12M
74.55M – 77.82M
+18.6% YoY
|
82.76M
81.06M – 84.61M
+8.7% YoY
|
92.89M
90.99M – 94.98M
+12.2% YoY
|
| EBITDA |
55.52M
est: 23.63M (+134.9%)
|
20.70M
est: 19.73M (+4.9%)
|
19.75M
est: 17.23M (+14.6%)
|
23.19M
est: 18.10M (+28.1%)
|
25.41M
est: 19.70M (+29.0%)
|
18.00M
est: 20.81M (-13.5%)
|
12.88M
est: 13.30M (-3.1%)
|
17.22M
est: 17.52M (-1.7%)
|
18.02M
est: 17.01M (+5.9%)
|
17.68M
17.58M – 17.85M
+3.9% YoY
|
19.81M
19.14M – 20.48M
+12.0% YoY
|
23.50M
23.02M – 24.03M
+18.6% YoY
|
25.55M
25.03M – 26.12M
+8.7% YoY
|
28.68M
28.09M – 29.32M
+12.2% YoY
|
| EBIT |
22.21M
est: -13.35M (+266.4%)
|
7.64M
est: -11.14M (+168.6%)
|
-12.76M
est: -9.73M (-31.2%)
|
-9.99M
est: -10.22M (+2.3%)
|
-4.85M
est: -11.13M (+56.4%)
|
-16.41M
est: -11.75M (-39.6%)
|
-19.06M
est: -7.07M (-169.4%)
|
-5.50M
est: -9.32M (+41.0%)
|
-4.18M
est: -9.05M (+53.8%)
|
-9.40M
-9.50M – -9.35M
-3.9% YoY
|
-10.53M
-10.89M – -10.18M
-12.0% YoY
|
-12.50M
-12.78M – -12.24M
-18.6% YoY
|
-13.59M
-13.89M – -13.31M
-8.7% YoY
|
-15.25M
-15.59M – -14.94M
-12.2% YoY
|
| Net Income |
-6.10M
est: -9.72M (+37.3%)
|
-24.81M
est: -29.06M (+14.6%)
|
-19.55M
est: -10.62M (-84.1%)
|
-15.33M
est: -11.44M (-34.0%)
|
-13.12M
est: -11.90M (-10.3%)
|
-23.60M
est: -20.45M (-15.4%)
|
-27.53M
est: -17.62M (-56.2%)
|
-19.66M
est: -19.25M (-2.1%)
|
-12.65M
est: -12.29M (-2.9%)
|
-10.25M
-10.54M – -9.96M
+16.6% YoY
|
-2.48M
-2.55M – -2.42M
+75.8% YoY
|
2.17M
2.11M – 2.23M
+187.7% YoY
|
7.45M
7.25M – 7.66M
+242.4% YoY
|
11.48M
11.17M – 11.81M
+54.2% YoY
|
| SGA |
15.43M
est: 37.46M (-58.8%)
|
18.79M
est: 31.28M (-39.9%)
|
24.35M
est: 27.31M (-10.9%)
|
31.39M
est: 28.69M (+9.4%)
|
32.06M
est: 31.23M (+2.6%)
|
35.58M
est: 32.98M (+7.9%)
|
28.29M
est: 20.91M (+35.3%)
|
26.93M
est: 27.55M (-2.2%)
|
22.00M
est: 26.75M (-17.7%)
|
27.80M
27.64M – 28.07M
+3.9% YoY
|
31.14M
30.09M – 32.19M
+12.0% YoY
|
36.94M
36.18M – 37.77M
+18.6% YoY
|
40.17M
39.34M – 41.07M
+8.7% YoY
|
45.08M
44.16M – 46.10M
+12.2% YoY
|
| EPS |
-0.24
est: -0.31 (+21.4%)
|
-0.92
est: -0.91 (-0.8%)
|
-0.67
est: -0.33 (-100.9%)
|
-0.48
est: -0.36 (-33.6%)
|
-0.41
est: -0.37 (-9.7%)
|
-0.73
est: -0.64 (-13.8%)
|
-0.85
est: -0.55 (-54.5%)
|
-0.62
est: -0.61 (-1.6%)
|
-0.40
est: -0.39 (-2.6%)
|
-0.32
-0.33 – -0.32
+16.7% YoY
|
-0.08
-0.08 – -0.08
+75.8% YoY
|
0.07
0.07 – 0.07
+187.5% YoY
|
0.24
0.23 – 0.24
+242.9% YoY
|
0.36
0.35 – 0.37
+54.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 12.1K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Craig Stuart Millian | Chief Executive Officer & Director | 1M | male |
| John Hanna | Chief Financial Officer & Non-Independent Director | 660.1K | male |
| Brian T. Walsh | Chief Commercial Officer | 616.3K | male |
| Ryan C. Lennox | Senior Vice President of Legal, HR & Compliance and Corporate Secretary | 507.2K | male |
| Jason A. Gross | Vice President of Scientific Affairs | 399.6K | — |
| David Spence | Vice President & Corporate Controller | — | male |
| Dave Mason | Investor Relations Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HLS.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
